Retatrutide timeline: what happened, what it means, and what still isn’t known
This page is a timeline, not a pitch. It tracks trial milestones, official updates, and source-backed context around retatrutide so readers can separate real developments from hype.
Educational only. No treatment, dosing, or longevity recommendations.
Fast path: what to track week to week (logging checklist)
If you’re trying to make sense of “is anything changing yet?”, a simple log is more useful than memory. This is about tracking and organization, not medical advice.
Basics
- Dose date + time (and if it was early/late)
- Injection site + notes (rotation)
- Appetite / satiety notes
- Nausea, constipation, reflux (if any)
- Sleep + energy
Helpful if you’re already measuring
- Weight trend (weekly is often enough)
- Waist or fit/size notes (optional)
- Glucose/A1C-related notes if relevant to you
- “Context” notes: travel, stress, illness, alcohol
Start here:
- Retatrutide tracker hub (routes to dose log, side-effect log, missed dose, and dose timing)
- Injection protocol tracker (simple template for consistent logging)
How to read this timeline
- Primary sources first: company releases, journals, official regulatory documents.
- Topline is not final: topline summaries are useful, but they are not the same as a full paper or label.
- Availability is separate: trial results do not automatically mean FDA approval, coverage, or broad access.
Retatrutide timeline
-
2023 to 2024, early major attention on retatrutide
Retatrutide drew attention as a multi-receptor incretin candidate in obesity and diabetes, with growing interest in how it might compare with current GLP-1 and dual-agonist therapies. At this stage, the key takeaway was still uncertainty: promising data is not the same as approved use.
-
March 2026, Phase 3 topline diabetes results reported
Eli Lilly reported topline results from the Phase 3 TRANSCEND-T2D-1 trial, describing reductions in A1C and weight over 40 weeks in type 2 diabetes. This is a real milestone, but still a topline summary rather than full peer-reviewed publication.
-
2026, continuing watch item: safety, labeling, and access
The next meaningful changes are not social-media enthusiasm. They are: fuller data publication, safety detail, regulatory milestones, and eventually label/coverage reality.
What matters next
- Fuller efficacy and safety publication
- Regulatory milestones or FDA updates
- Any label-relevant warning/contraindication detail
- Coverage and access implications if/when status changes
If you’re tracking your own timeline, these are the pages people tend to need most:
What this does not prove
- It does not prove retatrutide is appropriate for any individual reader.
- It does not justify “healthspan” or “life extension” claims on its own.
- It does not answer availability, affordability, or switching decisions without future regulatory and clinical context.